PROF Archives - Page 3 of 7

Developments

Profound Medical’s TULSA procedure featured at AUA

Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA procedure was featured in four presentations at the American Urological Association (AUA) annual meeting that reinforced its safety, efficacy and durability, further...

May 1, 2023

Developments

KOL urges offering Profound’s TULSA-PRO to prostate cancer patients as part of informed consent

Y. Mark Hong, M.D., a key opinion leader (KOL) and world recognized urologist, suggests that if physicians aren’t offering or at least talking to their prostate cancer patients about Profound Medical’s (NASDAQ:PROF;...

April 11, 2023

Markets

RJ highlights takeaways from KOL presentations on Profound’s TULSA-PRO

In a new report, Raymond James analyst, Rahul Sarugaser, Ph.D., outlined his five main takeaways from presentations from four key opinion leaders – Yale, UCLA, Mayo Clinic and WellSpan Health – about their clinical...

March 15, 2023

Markets

Raymond James, AGP up Profound Medical PTs as AMA to consider CPT approval

Raymond James raised its price target for Profound Medical (NASDAQ:PROF) to $17 from $15 and reiterated a “strong buy” rating after the company said its application for full CPT-1 reimbursement for TULSA-PRO has been...

March 8, 2023

Developments

Profound Medical CEO adds to holdings, again

According to a filing with SEDI, Profound Medical (NASDAQ:PROF; TSX:PRN) chairman and CEO, Arun Menawat, acquired 13,000 shares of the company at a price of $7.81 (U.S.) each on the open market to hold 425,296 shares...

December 21, 2022

Markets

Raymond James sees catalyst-rich two years ahead for Profound

Raymond James analyst, Rahul Sarugaser, Ph.D., outlined a series of potential catalysts for Profound Medical (NASDAQ:PROF; TSX:PRN), through 2023 and 2024 as it continues to commercialize its TULSA-PRO medical device to...

December 19, 2022

Developments

UT Southwestern performs 100th procedure with Profound’s TULSA-PRO

UT Southwestern in Dallas, one of the nation’s premier academic medical centers, performed its 100th procedure with Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO, an innovative MRI-guided minimally invasive...

December 9, 2022

Developments

Raymond James sees high likelihood of CPT-1 reimbursement for Profound’s TULSA-PRO

Analyst Rahul Sarugaser, Ph.D., writes that there is a high likelihood that Profound Medical (NASDAQ:PROF) will receive a category-1 CPT code from the Centers for Medicare and Medical Services when it files an...

November 15, 2022

Developments

Profound Medical presents durable and stable positive 4-year trends from TACT pivotal trial

An investigator for Profound Medical (NASDAQ:PROF; TSX:PRN) presented four-year follow-up data from the TACT clinical study with Profound’s TULSA-PRO device that continue to demonstrate durable and stable safety and...

September 26, 2022

Developments

Profound Medical realigns commercial organization to support continued growth

Profound Medical (NASDAQ:PROF; TSX:PRN) has changed its management team and structure to further position the company for continued sales success and global growth. Abbey Goodman and Hartmut Warnken have been appointed...

September 15, 2022

Tag - PROF

Profound Medical’s TULSA procedure featured at AUA

KOL urges offering Profound’s TULSA-PRO to prostate cancer patients as part of informed consent

RJ highlights takeaways from KOL presentations on Profound’s TULSA-PRO

Raymond James, AGP up Profound Medical PTs as AMA to consider CPT approval

Profound Medical CEO adds to holdings, again

Raymond James sees catalyst-rich two years ahead for Profound

UT Southwestern performs 100th procedure with Profound’s TULSA-PRO

Raymond James sees high likelihood of CPT-1 reimbursement for Profound’s TULSA-PRO

Profound Medical presents durable and stable positive 4-year trends from TACT pivotal trial

Profound Medical realigns commercial organization to support continued growth

Subscribe